Since the identification of CCR5 and CXCR4 as HIV coreceptors a little over a decade ago, there has been hope that coreceptor inhibitors will be able to make an impact on the HIV epidemic, both as novel therapeutic drugs and as agents used in prevention. Significant progress has been made in the understanding of how coreceptor choice might impact HIV pathology and how coreceptor blockade may affect health. In this review, we focus on some of the key issues that are emerging now that CCR5 has been validated as a promising target for HIV prevention strategies and at a time when a CCR5 inhibitor has been approved in the United States as the first in a new class of anti-HIV therapeutic drugs.

中文翻译：

---

针对艾滋病毒中的趋化因子受体：现状报告。

自从十几年前将CCR5和CXCR4鉴定为HIV共同受体以来，人们一直希望，共同受体抑制剂既可以作为新型治疗药物，也可以作为预防药物，对HIV流行产生影响。在理解共受体选择如何影响艾滋病毒病理以及共受体阻断如何影响健康方面的理解已取得重大进展。在本综述中，我们将重点关注一些新出现的关键问题，因为CCR5已被确认为HIV预防策略的有希望的靶标，并且在美国，CCR5抑制剂被批准为新药中的第一个抑制剂之时类抗HIV治疗药物。